BIOXYTRAN, INC: Business Overview, Financials & Competitive Analysis
BIOXYTRAN, INC scores 3/10 on the AskCyborg Cyborg Score (Weak). High-risk preclinical biotech pursuing novel oxygen therapeutics and antiviral platforms with uncertain clinical and commercial pathway. BIOXYTRAN is a micro-cap clinical-stage biotech with minimal revenue, only 3 employees, and a market cap under $10M as of late 2025. The company has multiple early-stage drug candidates but limited cash resources and.
What is BIOXYTRAN, INC's industry? BIOXYTRAN, INC (bioxytraninc.com) operates in Biotechnology. AskCyborg classifies BIOXYTRAN, INC under Biotechnology in its company registry.
BIOXYTRAN is a clinical-stage biotech company developing galectin-based antivirals and oxygen transport therapies for stroke, Alzheimer's, and viral diseases. The company focuses on development and commercialization o...
Cyborg Score thesis
High-risk preclinical biotech pursuing novel oxygen therapeutics and antiviral platforms with uncertain clinical and commercial...
Read the full analyst-debate transcript →Get the Latest BIOXYTRAN, INC Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBIOXYTRAN, INC Overview
Pro stress-test →BIOXYTRAN is a clinical-stage biotech company developing galectin-based antivirals and oxygen transport therapies for stroke, Alzheimer's, and viral diseases. The company focuses on development and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke.
Strategic Profile
Pro stress-test →The company highlights a core focus on broad-spectrum antiviral therapies, with its leading antiviral drug candidate ProLectin-M described as a complex carbohydrate therapeutic and galectin antagonist that targets viral entry mechanisms. The company's lead product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked.
Competitive Landscape
Pro stress-test →BIOXYTRAN competes in early-stage stroke therapeutics against clinical-stage and emerging biotech firms, as well as in antiviral drug development. Direct competition is fragmented across small-cap biotech focusing on niche therapeutic areas (hypoxia, viral infections). Larger pharmaceutical companies are not directly pursuing identical galectin-antagonist antiviral or oxygen-transport stroke platforms, reducing near-term competitive pressure but also suggesting smaller addressable markets.
Industry Context
BIOXYTRAN, INC operates in Biotechnology.
Key facts
Founded: 2008 · Headquarters: Newton, Massachusetts, US · Employees: 3 · Revenue: Estimated $0–$0.5M (no meaningful commercial revenue; clinical-stage biotech) · Market cap: $8.4M